论文部分内容阅读
目的 探讨全反式维甲酸（ ＡＴＲＡ） 联合５Ｆｕ 治疗裸鼠皮下ＳＧＣ ７９０１ 胃腺癌的疗效。方法 以ＡＴＲＡ１ ０００ μｇ／ｄ 口服； ５Ｆｕ ２７ ｍｇ／ｋｇ 腹腔注射，隔天给药； 联合用药组剂量减半。结果 ５Ｆｕ 、ＡＴＲＡ 及两者联合用均能抑制移植瘤生长，治疗７ 周后，体积抑瘤率分别为５６ ．８８ ％ 、４９ ．００ ％ 和７０ ．００ ％ ，瘤重抑瘤率分别为５１ ．６４ ％ 、５６ ．１０ ％ 和７６ ．９５ ％ ； ＡＴＲＡ 与５Ｆｕ 的抑瘤作用相似（ Ｐ＞ ０ ．０５） ，联合用药的抑瘤作用较ＡＴＲＡ、５Ｆｕ 单用的抑瘤作用明显增强（ Ｐ＜ ０ ．０５） ，且治疗剂量减少１／２ 。结论 ＡＴＲＡ 和５Ｆｕ 联合应用能相互增强其抗癌作用，临床中可采用联合分化诱导治疗胃癌。
Objective To investigate the efficacy of all-trans retinoic acid (ATRA) combined with 5Fu in the treatment of subcutaneous SGC 7901 gastric adenocarcinoma in nude mice. Methods ATRA 1 000 μg/d orally; 5Fu 27 mg/kg was injected intraperitoneally every other day; The dosage of the combination group was halved. Results The combination of 5Fu, ATRA, and both inhibited the growth of xenografts. After 7 weeks of treatment, the volume inhibition rate was 56. 88%, 49. 00 % and 70. At 00%, the tumor inhibition rate was 51. 64%, 56. 10% and 76. The antitumor effect of ATRA was similar to that of 5-FU (P> 0.05), and the anti-tumor effect of combination therapy was significantly stronger than that of ATRA and 5-Fu alone (P < 0.05). The therapeutic dose is reduced by 1/2. Conclusion The combination of ATRA and 5Fu can enhance their anti-cancer effects. Clinically, combined differentiation can be used to induce gastric cancer.